News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medarex, Inc. (MEDX) to Receive Milestone Payment from FibroGen, Inc. for the Initiation of a Phase 2 Study of FG-3019 in Patients with Diabetic Kidney Disease


7/13/2009 9:06:27 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Medarex, Inc. (NASDAQ:MEDX) today announced it will receive a milestone payment of an undisclosed amount from its licensing partner, FibroGen, Inc., in connection with a recently initiated Phase 2 clinical trial of FG-3019 in patients with type 2 diabetes and advanced kidney disease as announced by FibroGen on June 15, 2009.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES